Healthcare / BiotechnologyNasdaqGS
$4.38
+0.01 (+0.23%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-99.3M · quality 73.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$484M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-40.9%
↓Gross Margin
N/A
•Debt/Equity
0.23
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-276.2%
FCF / Net income
0.95x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $35.9M · net income $-105.0M · FCF $-99.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $35.9M | $35.9M | $35.6M | $20.8M | $31.1M | $45.8M | — | — |
| Net Income | $-105.0M | $-105.0M | $-105.3M | $-132.5M | $-128.2M | $-83.9M | $-66.3M | $-34.1M |
| EBITDA | $-102.5M | $-102.5M | $-115.4M | $-128.0M | $-124.3M | $-80.6M | $-58.8M | $-33.9M |
| EPS | — | — | -1.52 | -2.67 | -2.62 | -1.82 | -5.83 | -31.03 |
| Operating Margin | -290.7% | -290.7% | -329.3% | -669.8% | -416.6% | -179.4% | — | — |
| Net Margin | -292.1% | -292.1% | -296.0% | -638.3% | -412.2% | -183.2% | — | — |
| Balance Sheet | ||||||||
| Debt/Equity | 0.23 | 0.23 | 0.30 | 0.29 | 0.30 | 0.03 | 0.04 | — |
| Current Ratio | 9.01 | 9.01 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-99.3M | $-99.3M | $-65.3M | $-108.5M | $-111.4M | $-88.2M | $-67.9M | $54.3M |
| Returns | ||||||||
| ROE | -40.9% | -40.9% | -48.8% | -53.8% | -44.3% | -21.5% | -23.6% | 30.5% |
| Valuation | ||||||||
| P/B | 1.65 | 1.65 | 1.26 | 1.29 | 1.14 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | 1.0% | 1.0% | 71.4% | -33.3% | — | — | — | — |
| EPS Growth | — | — | 43.1% | -1.9% | — | 68.8% | 81.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+250.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.52 → n/d
Residual
+250.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.